Revere Pharmaceuticals | Rac1 GTPase

The power of the platform

We have developed a pipeline of novel small molecule compounds targeting key Rho GTPases by interrogating the biology of their deregulation with our drug discovery platform.

The foundation of our proprietary Rho GTPase platform is the customized suite of biochemical and cellular assays we have developed for Rac1 wild type and several variants and Cdc42. These assays inform our medicinal chemistry, structural biology, and computational modeling efforts for design and development of a diverse pipeline of Rac1 and Cdc42 inhibitors.

Target	Indications	Status
Wild type Rac1	HER2+ breast cancer progressing on HER2 targeted therapies ER+ breast cancer progressing on endocrine therapy + CDK 4/6 inhibitors Metastatic castrate resistant prostate cancer patients progressing on testosterone suppression therapy and AR inhibitors	Preclinical
Rac1b splice variant	Colorectal cancer progressing on chemotherapy	Preclinical
Rac1 P29S mutant	Melanoma progressing on immune checkpoint inhibitors, BRAF/MEK inhibitors	Preclinical

Target

Indications

Status

Wild type Rac1

HER2+ breast cancer progressing on HER2 targeted therapies

ER+ breast cancer progressing on endocrine therapy + CDK 4/6 inhibitors

Metastatic castrate resistant prostate cancer patients progressing on testosterone suppression therapy and AR inhibitors

Preclinical

Rac1b splice variant

Colorectal cancer progressing on chemotherapy

Preclinical

Rac1 P29S mutant

Melanoma progressing on immune checkpoint inhibitors, BRAF/MEK inhibitors

Preclinical

Our pipeline of novel small molecule compounds

The power of the platform

Our Pipeline

Learn More